Jefferies Financial Group set a €110.00 ($123.60) target price on Sanofi (EPA:SAN) in a research report report published on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also commented on SAN. UBS Group set a €101.00 ($113.48) target price on shares of Sanofi and gave the stock a buy rating in a report on Thursday, June 25th. Deutsche Bank set a €99.00 ($111.24) target price on shares of Sanofi and gave the stock a buy rating in a report on Tuesday, April 14th. JPMorgan Chase & Co. set a €103.00 ($115.73) target price on shares of Sanofi and gave the stock a buy rating in a report on Thursday, July 9th. Morgan Stanley set a €107.00 ($120.22) target price on shares of Sanofi and gave the stock a buy rating in a report on Tuesday, June 9th. Finally, Credit Suisse Group set a €105.00 ($117.98) price target on shares of Sanofi and gave the company a buy rating in a report on Friday, June 12th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Sanofi currently has an average rating of Buy and an average price target of €101.54 ($114.09).

SAN opened at €88.55 ($99.49) on Wednesday. The company has a fifty day moving average price of €91.31 and a two-hundred day moving average price of €87.93. Sanofi has a 52 week low of €63.09 ($70.89) and a 52 week high of €92.97 ($104.46).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: What defines an oversold asset?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.